Disciplined Investments’s Pacira BioSciences PCRX Stock Holding History

Disciplined Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$160	–	1139
2023 Q2	$160	Sell	4 -2	-33%	-$83	﹤0.01%	1537
2023 Q1	$245	Buy	6 +4	+200%	+$159	﹤0.01%	1448
2022 Q4	$77	Sell	2 -1	-33%	-$49	﹤0.01%	1552
2022 Q3	$0	Sell	3 -1	-25%	-$56	﹤0.01%	1508
2022 Q2	$0	Sell	4 -1	-20%	-$66	﹤0.01%	1524
2022 Q1	$0	Buy	+5	New	+$333	﹤0.01%	1546

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Disciplined Investments's PCRX Position: Q3 2023 in Review

Disciplined Investments sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 4 shares — an estimated $160 sold.

Disciplined Investments first reported a position in PCRX in Q1 2022 and held it in 6 quarters. The position peaked at $245 in Q1 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

Disciplined Investments reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
Disciplined Investments sold 4 Pacira BioSciences shares in Q3 2023, an estimated $160.
Disciplined Investments first reported a position in Pacira BioSciences in Q1 2022 and held it in 6 quarters.
Disciplined Investments's Pacira BioSciences position peaked at $245 in Q1 2023.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.